OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Discovery is 90. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Hallmarks of Cancer: New Dimensions	4348
Therapeutic Targeting of the Tumor Microenvironment	797
Liquid Biopsy: From Discovery to Clinical Application	502
Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors	459
The Next Decade of Immune Checkpoint Therapy	445
Spatiotemporal Immune Landscape of Colorectal Cancer Liver Metastasis at Single-Cell Level	419
A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti–PD-1 Agent Pembrolizumab	294
Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation	284
Artificial Intelligence in Cancer Research and Precision Medicine	278
Tumor-Infiltrating Natural Killer Cells	267
BI-3406, a Potent and Selective SOS1–KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition	256
The RNA m6A Reader YTHDF2 Maintains Oncogene Expression and Is a Targetable Dependency in Glioblastoma Stem Cells	244
Paradigms on Immunotherapy Combinations with Chemotherapy	237
Diffuse Glioma Heterogeneity and Its Therapeutic Implications	237
Single-Cell Atlas of Lineage States, Tumor Microenvironment, and Subtype-Specific Expression Programs in Gastric Cancer	233
Modes of Regulated Cell Death in Cancer	226
Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade	196
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy	189
Metastasis-Initiating Cells and Ecosystems	181
Metabolic Codependencies in the Tumor Microenvironment	179
Development of Immunotherapy Combination Strategies in Cancer	173
A Genetic Mouse Model Recapitulates Immune Checkpoint Inhibitor–Associated Myocarditis and Supports a Mechanism-Based Therapeutic Intervention	172
Clinicogenomic Analysis of FGFR2-Rearranged Cholangiocarcinoma Identifies Correlates of Response and Mechanisms of Resistance to Pemigatinib	171
Targeting Metabolic Plasticity and Flexibility Dynamics for Cancer Therapy	168
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial	168

Metastasis and Immune Evasion from Extracellular cGAMP Hydrolysis	164
Lower Airway Dysbiosis Affects Lung Cancer Progression	164
Priority COVID-19 Vaccination for Patients with Cancer while Vaccine Supply Is Limited	163
Fasting-Mimicking Diet Is Safe and Reshapes Metabolism and Antitumor Immunity in Patients with Cancer	162
Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors HarboringFGF/FGFRAberrations: A Phase I Dose-Expansion Study	157
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors	157
Venetoclax and Navitoclax in Combination with Chemotherapy in Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma	156
Comprehensive Genomic and Transcriptomic Analysis for Guiding Therapeutic Decisions in Patients with Rare Cancers	153
Targeting the p300/CBP Axis in Lethal Prostate Cancer	150
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer	149
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence	149
Somatic HLA Class I Loss Is a Widespread Mechanism of Immune Evasion Which Refines the Use of Tumor Mutational Burden as a Biomarker of Checkpoint Inhibitor Response	149
Outlook for New CAR-Based Therapies with a Focus on CAR NK Cells: What Lies Beyond CAR-Engineered T Cells in the Race against Cancer	145
Detecting Liquid Remnants of Solid Tumors: Circulating Tumor DNA Minimal Residual Disease	143
Efficacy of a Small-Molecule Inhibitor of KrasG12D in Immunocompetent Models of Pancreatic Cancer	139
Independent Drug Action in Combination Therapy: Implications for Precision Oncology	138
Overcoming Resistance to Tumor-Targeted and Immune-Targeted Therapies	137
Identification of Functional Heterogeneity of Carcinoma-Associated Fibroblasts with Distinct IL6-Mediated Therapy Resistance in Pancreatic Cancer	137
Gut Microbiome Directs Hepatocytes to Recruit MDSCs and Promote Cholangiocarcinoma	136
WNT as a Driver and Dependency in Cancer	136
The Lipogenic Regulator SREBP2 Induces Transferrin in Circulating Melanoma Cells and Suppresses Ferroptosis	135
The Pediatric Precision Oncology INFORM Registry: Clinical Outcome and Benefit for Patients with Very High-Evidence Targets	135
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures	135
Expanding the Reach of Precision Oncology by Drugging All KRAS Mutants	135
Therapeutically Increasing MHC-I Expression Potentiates Immune Checkpoint Blockade	134
St. Jude Cloud: A Pediatric Cancer Genomic Data-Sharing Ecosystem	134
Determinants of Response and Intrinsic Resistance to PD-1 Blockade in Microsatellite Instability–High Gastric Cancer	129
Mobocertinib (TAK-788): A Targeted Inhibitor ofEGFRExon 20 Insertion Mutants in Non–Small Cell Lung Cancer	121
Mesenchymal Lineage Heterogeneity Underlies Nonredundant Functions of Pancreatic Cancer–Associated Fibroblasts	117
Netrin G1 Promotes Pancreatic Tumorigenesis through Cancer-Associated Fibroblast–Driven Nutritional Support and Immunosuppression	116
Synthetic Lethality in Cancer Therapeutics: The Next Generation	114
Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing	114
The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution	112
Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity	112
Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab	112
Spatial Positioning and Matrix Programs of Cancer-Associated Fibroblasts Promote T-cell Exclusion in Human Lung Tumors	111
Myeloid-Derived Suppressor Cells: A Propitious Road to Clinic	111
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity	109
A Natural Polyphenol Exerts Antitumor Activity and Circumvents Anti–PD-1 Resistance through Effects on the Gut Microbiota	108
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That Enhances CTLA4 Blockade on PD-1+ Activated T Cells	107
Longitudinal Undetectable Molecular Residual Disease Defines Potentially Cured Population in Localized Non–Small Cell Lung Cancer	106
Anti-Inflammatory Drugs Remodel the Tumor Immune Environment to Enhance Immune Checkpoint Blockade Efficacy	104
A Procarcinogenic Colon Microbe Promotes Breast Tumorigenesis and Metastatic Progression and Concomitantly Activates Notch and β-Catenin Axes	104
A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy	104
Fueling the Fire: Inflammatory Forms of Cell Death and Implications for Cancer Immunotherapy	101
Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative	100
Intraventricular B7-H3 CAR T Cells for Diffuse Intrinsic Pontine Glioma: Preliminary First-in-Human Bioactivity and Safety	100
Integrative Bulk and Single-Cell Profiling of Premanufacture T-cell Populations Reveals Factors Mediating Long-Term Persistence of CAR T-cell Therapy	100
Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia	99
A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy	98

IFNγ Is Critical for CAR T Cell–Mediated Myeloid Activation and Induction of Endogenous Immunity	98
KEAP1/NFE2L2 Mutations Predict Lung Cancer Radiation Resistance That Can Be Targeted by Glutaminase Inhibition	98
Pharmacologic Activation of p53 Triggers Viral Mimicry Response Thereby Abolishing Tumor Immune Evasion and Promoting Antitumor Immunity	98
Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?	96
Leukocyte Heterogeneity in Pancreatic Ductal Adenocarcinoma: Phenotypic and Spatial Features Associated with Clinical Outcome	95
Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial	95
IFNα Potentiates Anti–PD-1 Efficacy by Remodeling Glucose Metabolism in the Hepatocellular Carcinoma Microenvironment	94
Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia	94
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma	92
The European MAPPYACTS Trial: Precision Medicine Program in Pediatric and Adolescent Patients with Recurrent Malignancies	92
A CRISPR/Cas9-Engineered ARID1A-Deficient Human Gastric Cancer Organoid Model Reveals Essential and Nonessential Modes of Oncogenic Transformation	92
Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders	91
CRISPR Screening of CAR T Cells and Cancer Stem Cells Reveals Critical Dependencies for Cell-Based Therapies	91
Implementing a Functional Precision Medicine Tumor Board for Acute Myeloid Leukemia	91
A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era	91
Tracking Cancer Evolution through the Disease Course	90
Endogenous Retroelements and the Viral Mimicry Response in Cancer Therapy and Cellular Homeostasis	90